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i. Running Head: Host-derived biomarkers for Chagas disease diagnosis. 13 
 14 
ii. Summary/Abstract  15 
The most severe clinical symptomatology of Chagas disease affects ~30% of those chronically 16 
infected with the Trypanosoma cruzi parasite. The pathogenic mechanisms that lead to life-17 
threatening heart and gut tissue disruptions occur “silently” for a longtime in a majority of cases. As a 18 
result, despite there are several serological and molecular methods available to diagnose the infection 19 
in its acute and chronic stages, diagnosis is often achieved only after the onset of clinical symptoms in 20 
the chronic phase of the disease. Furthermore, although there are two drugs to treat it, the assessment 21 
of their performance is impractical with current parasite-derived diagnostics and therapeutic efficacy 22 
cannot be acknowledged in a timely manner.   23 
In this chapter we present two procedures to measure host derived molecules as surrogates of 24 






activity of thrombin, a major component of the blood coagulation cascade. This is due to the fact that 26 
a hypercoagulability state has been described to occur in chronic Chagas disease patients, and revert 27 
after treatment with benznidazole.  28 
 29 
iii. Key Words: Chagas disease, diagnosis, prognosis, therapeutic response, host-derived 30 
biological markers, hypercoagulability biomarkers. 31 
 32 
1. Hypercoagulability markers in plasma: introduction and protocols  33 
1.1 Introduction 34 
Chagas disease is a complex entity in terms of pathobiology, and complex is the life cycle of its 35 
etiological agent: the protozoan parasite T. cruzi. It involves insect and mammalian infective forms, 36 
which in the human host are capable of infecting several host cell types and tissues to propagate the 37 
infection [1]. During its acute phase there is a strong immunological response as the presence of T. cruzi 38 
produces an inflammatory reaction and the secretion of pro-inflammatory cytokines, as well as parasite-39 
specific polyclonal antibodies and activation of effector T cells [2, 3]. Despite this response, the parasite 40 
is well-dotted with anti-immune mechanisms and manages to persist leading to a chronic infectious state 41 
without causing any overt symptomatology for years. This “silent” clinical feature of Chagas disease 42 
largely hinders the clinical diagnosis of the infection before the onset of more severe symptoms [4]. These 43 
will affect ~30% of those chronically infected, who will suffer from damage at the heart and/or at the 44 
esophagus and colon. It is when tissue disruption occurs that several unspecific inflammatory mediators 45 
appear altered. Before reaching this point, it would be of major relevance to have a way of ascertaining 46 
the disease prognosis, including the evaluation of the administration of benznidazole (BNZ) or nifurtimox 47 
(NFX) treatments. This would mean a huge advantage for the daily clinical management of the disease, as 48 
well as for the clinical testing of any new drug regimens or novel anti-parasitic compounds. 49 






At present, there are serological and molecular diagnostics based on the respective detection of 51 
anti-T. cruzi immunoglobulins or parasite-derived DNA sequences [5, 6]. They provide valuable 52 
information on the infection status, but cannot inform on the clinical prognosis of the disease; and despite 53 
recent advancements [7], they cannot yet be used to address treatment efficacy (or spontaneous cure) 54 
either. This is because a positive serological result takes many years to become negative making serology 55 
impractical for response-to-treatment assessment. Whereas regarding highly sensitive molecular-based 56 
techniques, although a positive detection certainly indicates there are circulating parasites, a negative 57 
result cannot rule out a latent very low parasitemia or the presence of tissue hidden forms that could 58 
relapse later on. Thereby, in view of the absence yet of markers to address disease prognosis and/or 59 
therapeutic response in the parasite, host-derived markers have also become a source of interest.    60 
Even though host-parasite interactions and their role in the progression of the disease are still not 61 
well known, several host biomarkers of T. cruzi infection have been identified during the last decade [8]. 62 
Moreover, their use as diagnostics to evaluate therapeutic response has been investigated [8]. In this 63 
regard, there are three main groups of host-derived molecules: (i) immunological markers (cytokines and 64 
surface markers) elicited by the host cellular response to the infection [9, 10]; (ii) biochemical 65 
biomarkers, such as hypercoagulability markers, fragments of apolipoprotein A1 (ApoA1), tumor necrosis 66 
factor (TNF) or transforming growth factor beta (TGFβ) [11–13]; and (iii) inflammatory markers of 67 
cardiac damage (e.g. type-B natriuretic peptide (BNP) or highly-sensitive protein C), which have been 68 
perhaps the most studied, and shown to be not very good to follow disease progression [14]. 69 
 It has been previously described that a hypercoagulability state can appear in people with T. cruzi 70 
infection [11, 15, 16]. In the context of an infectious disease, this hypercoagulability could be due to three 71 
processes: (a) dysregulation of immunothrombosis [17]; (b)  platelet adhesion events driven by a chronic 72 
inflammation state [18]; and (c) vasculitis caused by the chronic infection [19]. Altogether they can lead 73 
towards increased levels of pro-inflammatory cytokines, and therefore perpetuate the risk of thrombotic 74 






Amongst the different blood coagulation markers involved in the aforementioned processes, two 76 
were significantly elevated in Chagas disease patients in comparison to controls and could thereof be used 77 
as biomarkers of T. cruzi infection diagnosis and response-to-treatment assessment [16] (Figure 1). The 78 
hypercoagulability markers prothrombin fragment 1+2 (F1+2) and endogenous thrombin potential (ETP) 79 
were abnormally expressed in a high percentage of patients with chronic T.cruzi infection before 80 
treatment (77% and 50%, respectively). Shortly after BNZ treatment both returned to, and remained at 81 
normal levels in 76% and 96% of patients, respectively [16]. The performance of F1+2 and ETP fulfilled 82 
the Target Product Profile (TPP) defined for chronic Chagas disease response-to-treatment biomarkers [8, 83 
16].  84 
It cannot be disregarded that both hypercoagulability biomarkers (F1+2 and ETP) presented with 85 
normal values in a percentage of T. cruzi-infected people, which may limit their usefulness as universal 86 
biomarkers [16]. Another big limitation is that current procedures to measure them share a common 87 
requirement for high-technological equipment and highly-trained technical personnel to run it. This is a 88 
setback for their application in many ill-equipped laboratories from Chagas disease endemic regions at the 89 
moment. Indeed there is yet a lot of work ahead, and more resources and attention should be placed on the 90 
matter.  91 
In this chapter, we describe the rational and protocol procedures to implement the detection of 92 
presently most promising host-derived biomarkers for Chagas disease response-to-treatment assessment. 93 
These are the hypercoagulability biomarkers F1+2 Enzyme-Linked Immunosorbent Assay (Protocol 1), 94 
and Endogenous Thrombin Potential (ETP) Kinetics Assay (Protocol 2) [16]. 95 
 96 
1.2 Protocol 1: F1+2 Enzyme-Linked ImmunoSorbent Assay 97 
The proteolytic cleavage of prothrombin into active thrombin is a key step in the blood 98 
coagulation cascade. Thrombin activation is accompanied by formation of fragment F1+2. Thus, 99 






of F1+2 in plasma samples it is possible to diagnose prothrombotic states in comparison to plasma control 101 
samples. Levels of F1+2 can be detected with an immunochemical assay, such as the Enzygnost F1+2 102 
that is commercialized by Siemens Healthcare (reference number OPBD03; Marburg, Germany). This is 103 
an enzyme-linked immunosorbent assay (ELISA) based on an F1+2-specific monoclonal antibody (mAb). 104 
It is a sandwich ELISA because the antigen to detect (F1+2) is first bound by mAb that come attached to 105 
the assay wells. In a second incubation step, another antibody, specific against another antigenic 106 
determinant of F1+2 is added in to close the sandwich. This latter antibody is conjugated to a peroxidase 107 
(POD) enzyme and thus the presence of sandwich complexes can be evaluated with the addition of a 108 
chromogenic substrate of the POD reaction. The optical density (OD) value is proportional to the 109 
concentration of F1+2, the higher the absorption the higher is the concentration of F1+2 in the plasma 110 
sample (Figure 2). The concentration of F1+2 in the samples is calculated by comparing the OD of the 111 
samples to the calibration curve made with standard specimens. 112 
 113 
1.3 Protocol 2: Endogenous Thrombin Potential (ETP) Kinetics 114 
The Endogenous Thrombin Potential (ETP) is a test that reflects the capacity of a sample to 115 
generate thrombin considering both formation and inhibition. ETP can be determined measuring the 116 
conversion kinetics of a synthetic thrombin substrate. ETP test is performed by means of a commercial 117 
assay (i.e. ETP Innovance by Siemens Healthcare) and the required corresponding piece of equipment 118 
(i.e. Siemens BCS System). These resources are available in several hospital Hemostasis units.  119 
The synthetic thrombin substrate included in the kit contains a chromophore that is released upon 120 
its thrombin-mediated catalysis, therefore providing a chromogenic readout of thrombin activity in the 121 
plasma samples. The BCS System records absorbance at 405 nm in a continuum to evaluate the 122 
enzymatic kinetics of thrombin activity. BCS can also calculate the test output values. It first corrects with 123 
a mathematical algorithm for the thrombin bound to α2-macroglobulin so that the corrected curve shows 124 






automatically performed by the BCS equipment. The area under the corrected curve (AUC) and the 126 
curve´s peak height (Cmax) have been shown to be of diagnostic relevance. They can be obtained by an 127 
specific additional software (provided by the manufacturer) from the thrombin generation curve, that is 128 
the first derivative of the corrected curve.  129 
 130 
2. Materials 131 
This section is organized to list out all reagents and equipment required to perform the 132 
aforementioned protocols. 133 
2.1. F1+2 ELISA (Protocol 1) 134 
1. Preparation of plasma sample specimens.  135 
a. Venous blood samples (see Notes 1 to 3 in Protocol 1). 136 
b. Sodium citrate 3.2% solution (0.11 g/L). 137 
c. Table top centrifuge and rotor capable of 2,500 g centrifugation.  138 
2. Materials provided by the ELISA kit (ref. OPBD03; Siemens Healthcare) (see Note 4 in Protocol 139 
1). 140 
a. Enzygnost anti-F1+2 mouse mAb coated wells in strips format. Concentration of the mAbs 141 
may range from 10 to 100 µg per well depending on the lot. 142 
b. Microtiter assay plates to mount the strips in to perform the test.  143 
c. Anti-human prothrombin-POD conjugated antibody. This is also a mouse mAb which 144 
concentration can range from 2 to 20 mg/L depending on the lot.   145 
d. Conjugate buffer: Tris-HCl buffer provided by the manufacturer that contains Tween and 146 
bovine serum albumin. 147 
e. Human prothrombin F1+2 Standards 1 to 4 to make the standard curve with them. Their 148 
concentrations respectively range from ~20 to ~1,200 pmol/L (depending on the specific lot) 149 






f. Control plasma: lyophilized human plasma with F1+2 value as assigned in the 151 
corresponding lot. 152 
g. Sample buffer to dilute samples: Tris-HCl buffer that contains Tween and sodium chloride 153 
(NaCl).  154 
h. Washing solution: phosphate buffer containing Tween provided by the manufacturer. 155 
i. Buffer solution for dilution of TMB substrate containing hydrogen peroxide (H2O2) in 156 
acetate buffer. 157 
j. Tetramethyl benzidine dihydrochloride (TMB) chromogenic substrate. 158 
k. Stopping solution to stop the POD reaction: sulfuric acid (H2SO4) at 0.25 mol/L.  159 
3. Materials not provided by the kit. 160 
a. Micro-pipettes of variable volume dispensing capacities (from 50 µL to 1 mL), and multi-161 
channel pipette suitable to dispense from 50 µL up to 300 µL. 162 
b. Water bath for 37 ºC incubation steps. 163 
c. Microplate spectrophotometer reader to capture absorbance at 450 and 650 nm. 164 
d. Microplate washer and aspiration system for easier performance of washing steps 165 
(optional).  166 
 167 
2.2. Endogenous Thrombin Potential (ETP) Kinetics (Protocol 2) 168 
1. Preparation of plasma sample specimens: it is the same as that referred for Protocol 1 (see section 169 
2.1) (see Notes 1 to 3 in Protocol 2). 170 
2. Reagents included in the ETP kit (see Note 4 in Protocol 2). 171 
a. ETP Reagent containing fibrin aggregator inhibitor, chromogenic substrate, salts and 172 
stabilizer. 173 
b. Calcium chloride (CaCl2) solution at 250 mM. 174 






3. Reagents not included in the kit. (See Note 5 in Protocol 2). 176 
a. Innovin Reagent (Innovin is a recombinant thromboplastin reagent). 177 
b. ETP Standard (ETP Standard can be purchased to the same manufacturer than ETP). 178 
4. Equipment: the hemostasis analyzer for the ETP assay by Siemens Healthcare is the BCS System 179 
(see Note 6 in Protocol 2). 180 
 181 
3. Methods 182 
3.1. F1+2 ELISA (Protocol 1) 183 
1. Obtain venous blood mixing 9 parts of blood with 1 part of sodium citrate solution 3.2% (0.11 184 
mol/L).  185 
2. Centrifuge the mix for 15 minutes at 2,500 g. 186 
3. Get the upper supernatant plasma, taking care not to carry over platelets as well.  187 
4. Fresh plasma samples can be stored at room temperature (15 to 25 ºC) for 4 hours or in the 188 
fridge (2 to 8 ºC) for 8 hours until use. If longer storage is required, samples can stay frozen 189 
below -60 ºC in cap sealed tubes for up to 6 months (see Notes 2 and 5 in Protocol 1). 190 
5. Following the manufacturer instructions prepare the following solutions: “Washing solution”, 191 
“Conjugate solution”, and “Chromogen working solution”. All reagents and samples must be at 192 
room temperature before starting the procedure.   193 
6. Pick up the number of strips required considering that all determinations (standards 1 to 4), 194 
control samples and patients samples) must be done in duplicate (ensuring the coefficient of 195 
variation (CV) is ≤ 15%) (see Note 6 in Protocol 1). 196 
7. Add 50 µL of Sample buffer into each well. Then add 50 µL of standards, controls and samples 197 
where corresponding. Agitate the plate thoroughly (e.g. by aspirating and dispensing in well 198 






8. Cover the plate with an adhesive foil and incubate for 30 minutes at 37 ºC in a water bath (see 200 
Note 7 in Protocol 1).   201 
9. Remove the foil, aspirate the content of the wells and wash 2X by addition of 300 µL of 202 
“Washing solution” per well. Remove any remaining “Washing solution” by tapping the inverted 203 
plate on tissue paper.  204 
10. Add in 100 µL per well of “Conjugate solution”, not dispensing it onto the edge of the well. 205 
11. Cover with foil and incubate for 15 minutes at 37 ºC. 206 
12. Remove the foil, aspirate the wells contain and wash 3X as described earlier. Tap the inverted 207 
plate a few times against tissue paper to get rid of any “Conjugate solution” remainders. 208 
13. Add in 100 µL per well of “Chromogen solution”.  209 
14. Cover with foil and incubate for 15 minutes at room temperature (15 to 25 ºC) keeping the 210 
plate light-protected. 211 
15. Remove the foil and add in 100 µL per well of Stopping solution. 212 
16. Measure Absorbance within an hour time reading the plate with a spectrophotometer at 450 213 
nm and 650 nm wavelengths. 214 
17. To evaluate results calculate mean absorbance values of duplicates. Construct a reference 215 
curve with the Standards values (X-axis F1+2 concentration range from 20 to 1200 pmol/L; Y-216 
axis reflecting Absorbance at 450 nm ranging from 0.01 to 3). F1+2 concentrations of controls 217 
and samples can be directly extracted from the reference curve using their calculated mean 218 
absorbance values. Healthy donor control samples concentrations are expected to fall within an 219 
interval of reference values (see Note 8 in Protocol 1). F1+2 values above that reference range 220 
can indicate a hypercoagulable state (see Notes 9 and 10 in Protocol 1); whereas values below it 221 
can indicate hypocoagulable state. Please, be aware that a series of interfering substances in the 222 







3.2. Endogenous Thrombin Potential (ETP) Kinetics (Protocol 2) 225 
1. Obtain venous blood mixing 9 parts of blood with 1 part of sodium citrate solution 3.2% (0.11 226 
mol/L). 227 
2. Centrifuge the mix for 15 minutes at a 2,500 g. 228 
3. Get the upper supernatant plasma, taking care not to carry over platelets as well.  229 
4. Fresh plasma samples can be stored at room temperature (15 to 25 ºC) for 4 hours until use. If 230 
longer storage is required, freeze them below -60 ºC in cap sealed tubes.  231 
5. Plasma controls for normal ETP range (control negative pool) and pathological ETP range (control 232 
positive pool) must be made in advance and stored aliquoted in cap sealed tubes below -60 ºC until 233 
needed. Confidence intervals of these controls should be calculated and established at ±2.5 standard 234 
deviations from their median value (see Note 7 in Protocol 2). Controls will be treated as samples 235 
and included in each run. Please, be aware that a series of interfering substances in the samples may 236 
interfere with the test output (see Note 8 in Protocol 2).         237 
6. Thrombin formation in the samples and controls is driven by addition of Innovin Reagent 238 
(Siemens Healthcare) and calcium chloride. 239 
7. The assay runs over 20 minutes during which the thrombin continuous kinetics is displayed by the 240 
BCS System (Note 9 in Protocol 2). 241 
8. The test output is the end value of ETP conversion or the AUC of the kinetics corrected curve 242 
since both are proportional. Both parameters are automatically provided by the BCS System installed 243 
software (Note 10 in Protocol 2). 244 
 245 
4. Notes 246 
 Please be aware that Notes are enumerated per Protocol in the corresponding text above and 247 







F1+2 ELISA. Protocol 1 250 
1. Improper collection of blood samples or insufficient mixing with citrate solution may lead to 251 
falsely elevated F1+2 values. A clean venipuncture is essential. The required minimum draw 252 
volume is 2.7 mL blood in a 3 mL tube. Do not use the first 2 mL of blood collected. Mix 253 
thoroughly the tube by gentle inversion immediately after venipuncture. 254 
2. Do not refrigerate the whole blood tubes. Prothrombin F1+2 is unstable at room temperature and 255 
tubes must be processed and frozen within four hours of sample collection. 256 
3. Sample rejection causes are clotted sample, overfilled or underfilled tube, mislabeled or unlabeled 257 
sample. 258 
4. Good performance of the test is guaranteed only if reagents have the same lot number or the 259 
required combination of lot numbers is used.  260 
5. It is not possible to measure F1+2 with Enzygnost monoclonal antibody out of samples that have 261 
been frozen and thawed repeatedly. 262 
6. Each experiment and each plate used within must include its own standard curve using the 263 
provided standard samples 1 to 4. Besides, the “Control plasma” supplied with the kit has to be 264 
tested along with each series of samples. To validate the test, “Control plasma” sample F1+2 265 
concentration must fall within the expected range as determined in the kit lot instructions.   266 
7. Be aware that plate filling must be completed within ten minutes and the incubation time starts 267 
when the plate is placed in the water bath at 37 ºC. 268 
8. Median value of F1+2 from healthy adults´ citrated plasma (n=137) was reported to be 115 269 
pmol/L (with 5th to 95th reference range percentile of 69 to 229 pmol/L). This reference interval 270 
may vary from lab to lab and that is why each laboratory should establish its reference working 271 
interval. If any Absorbance values exceed that of the highest standard, such samples will have to 272 
be re-tested diluted (maximum 1:20) in Sample buffer. Be aware of the dilution factor to correct 273 






9. Plasma F1+2 levels are increased in patients with renal failure. 275 
10. Since Enzygnost F1+2 detection procedure is based on a F1+2 specific monoclonal antibodies, be 276 
aware that patients who have received preparations of mouse monoclonal antibodies may yield 277 
falsely elevated results.  278 
11. In relation to interfering substances present in the plasma samples, it has been reported that 279 
Enzygnost F1+2 can work with levels of: bilirubin up to 60 mg/dL, free hemoglobin up to 600 280 
mg/dL, lipids up to 3000 mg/dL, and rheumatoid factors up to 197 IU/mL. 281 
 282 
Endogenous Thrombin Potential (ETP) Kinetics. Protocol 2   283 
1. Improper collection of blood samples or insufficient mixing with citrate solution may lead to 284 
erroneous ETP values. A clean venipuncture is essential. The required minimum draw volume is 285 
2.7 mL blood in a 3 mL tube. Do not use the first 2 mL of blood collected. Mix thoroughly the 286 
tube by gentle inversion immediately after venipuncture. 287 
2. Do not refrigerate the whole blood tubes. Tubes for ETP determination must be processed and 288 
frozen within four hours of specimen collection.  289 
3. Sample rejection causes are clotted sample, overfilled or underfilled tube, mislabeled or unlabeled 290 
sample.  291 
4. We have previously used an ETP kit provided by Dade Behring (reference number OPDS05; 292 
Marburg, Germany). Siemens Healthcare now provides a product called ETP Innovance, which is 293 
CE-marked and thus useful for research as well as for diagnostic purposes.   294 
5. Innovin Reagent is purchased from Siemens (reference number B4212). Similarly occurs with the 295 
ETP Standard (reference number OPDR05). 296 
6. ETP kit can only be used in the BCS System. 297 
7. Repetitive freeze-thaw cycles will damage control samples integrity. Therefore it is encouraged to 298 






volumes. If the values of the control samples included in the run are outside their predetermined 300 
confidence intervals, the controls, the test reagents, and the BCS analyzer must be checked. 301 
8. Icteric, hemolytic and lipemic samples may interfere with the procedure. 302 
9. BCS System rotor cuvette can run 20 samples in each run. Since measurement takes relatively 303 
long time (20 minutes), ETP should be performed in batches since no other test can be made in 304 
the BCS whilst ETP is running.        305 
10. Current BCS System does have checking algorithms for the ETP assay. If visual inspection of 306 
thrombin kinetics curves by operator, plausible kinetics must follow an initial linear rapid rise 307 
that then reaches a lag (plateau) phase with a much slower linear rise. ETP Standard Plasma curve 308 
can be used for comparison (see Figure 3). Invalid kinetics may show multiple rising phases, or 309 
an uneven linear growth at the end of the reaction time. Curves that have falling sections are not 310 
valid either and should be repeated. 311 
 312 
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Figure captions. 375 
 376 
Figure 1. Scheme of the blood coagulation cascade. Hypercoagulability biomarkers of the present chapter 377 
are highlighted in bold. 378 
 379 
Figure 2. Graph illustrating a typical calibration curve of F1+2. 380 
 381 
Figure 3. Plot of the measured total conversion and the calculated thrombin kinetics of a plasma sample. 382 
Y-axis shows the level of conversion of the synthetic substrate, whereas time of reaction is represented in 383 
the X-axis. 384 
 385 
